Comparing BioLineRx (NASDAQ:BLRX) and PMV Pharmaceuticals (NASDAQ:PMVP)

BioLineRx (NASDAQ:BLRX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

This table compares BioLineRx and PMV Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18 million	8.22	-$1.17 million	($0.17)	-13.12
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.97

BioLineRx has higher revenue and earnings than PMV Pharmaceuticals. BioLineRx is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioLineRx has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioLineRx and PMV Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1	0	1	1	2.67
PMV Pharmaceuticals	1	0	0	1	2.50

Profitability

This table compares BioLineRx and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
PMV Pharmaceuticals	N/A	-59.07%	-54.19%

Institutional and Insider Ownership

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioLineRx beats PMV Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.